Rationale: Asthma patients with severe disease are often prescribed a combination of high-dose ICS/LABA. We sought to better understand medical resource use in asthma patients receiving the highest approved combination dosage of fluticasone/salmeterol by examining healthcare service and pharmaceutical claim records.
Rationale: According to the National Asthma Education and Prevention Program (NAEPP) guidelines, asthma patients with severe disease -defined as Step 5 or 6 of these guidelines --are prescribed a combination of high-dose inhaled corticosteroid (ICS) and long-acting beta-agonists (LABA) as the preferred line of therapy. The purpose of this study was to analyze the medical service utilization patterns of patients on the highest dose of fluticasone/salmeterol combination medication (i.e. Advair 500), and to better understand the impact of medication compliance on medical resource use in this patient population, by examining healthcare service and pharmaceutical claim records.
Methods:

 Study Population
Patients meeting study criteria were selected from ThomsonReuters MarketScan claims databases covering private insurance and Medicare patients, and including inpatient, outpatient, and pharmaceutical healthcare service claims. 
Conclusion:
In this population of severe asthma patients, despite receiving care as prescribed in
Step 5 and 6 of the National Asthma Education and Prevention Program (NAEPP) guidelines (i.e. fluticasone/salmeterol 500/50), medical service utilization remained high. While being on fluticasone/salmeterol 500/50 reduced medical service utilization, this reduction was not significant until patient compliance reached 95% or greater. Since less than 10% of patients demonstrated a greater than 95% compliance rate over the follow-up period, it would be reasonable to conclude that even when patients with severe asthma are treated according to current guidelines, they still demonstrate significant health care utilization in emergency room visits and admissions to hospital. This observation is in keeping with the findings reported by the NIH Severe Asthma Research Program (SARP) report on characterization of severe asthma 1 .
This study confirms that full compliance is uncommon in patients with severe asthma, and that treatment of these patients with the highest approved dosage of fluticasone/salmeterol 500/50, is insufficient to significantly reduce health care utilization in this population.
